CORC

在结果中检索

CORC

浏览/检索结果: 共16条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang
收藏  |  浏览/下载：92/0  |  提交时间：2022/03/28
Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer 期刊论文
FRONTIERS IN PHARMACOLOGY, 2021, 卷号: 12
作者:  Yang, ZiYan;  Wang, Wei;  Wang, Xiaojia;  Qin, ZhiQuan
收藏  |  浏览/下载：37/0  |  提交时间：2022/01/10
An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer 期刊论文
CANCER MEDICINE, 2020, 页码: 12
作者:  Pan, Deng;  Tang, Yubo;  Tong, Jiao;  Xie, Chengmei;  Chen, Jiaxi
收藏  |  浏览/下载：17/0  |  提交时间：2020/12/24
YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer 期刊论文
BRITISH JOURNAL OF CANCER, 2020, 页码: 12
作者:  Wang, Lei;  Wang, Quanren;  Xu, Piaopiao;  Fu, Li;  Li, Yun
收藏  |  浏览/下载：15/0  |  提交时间：2020/12/24
DNA Origami-Enabled Engineering of Ligand-Drug Conjugates for Targeted Drug Delivery 期刊论文
SMALL, 2020, 卷号: 16, 期号: 16, 页码: -
作者:  Ge, ZL;  Guo, LJ;  Wu, GQ;  Li, J;  Sun, YL
收藏  |  浏览/下载：42/0  |  提交时间：2021/09/06
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:  Li, Qiao;  Guan, Xiuwen;  Chen, Shanshan;  Yi, Zongbi;  Lan, Bo
收藏  |  浏览/下载：15/0  |  提交时间：2020/07/01
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer 期刊论文
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 卷号: 380, 期号: 7
作者:  Wuelfing, P.;  Mano, M. S.;  Loibl, S.;  Mamounas, E. P.;  Untch, M.
收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05
KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer 会议论文
作者:  Mamounas, Eleftherios P.;  Geyer, Charles E., Jr.;  Huang, Chiun-Sheng;  Mano, Max S.;  Loibl, Sibylle
收藏  |  浏览/下载：21/0  |  提交时间：2019/12/05
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE 会议论文
作者:  Geyer, C. E., Jr.;  Huang, C-S;  Mano, M. S.;  Loibl, S.;  Mamounas, E. P.
收藏  |  浏览/下载：27/0  |  提交时间：2019/12/05
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer 期刊论文
CANCER SCIENCE, 2018, 卷号: 109, 期号: 10, 页码: 3305-3315
作者:  Wang, Lei;  Wang, Quanren;  Gao, Mingzhao;  Fu, Li;  Li, Yun
收藏  |  浏览/下载：50/0  |  提交时间：2019/01/08

©版权所有 ©2017 CSpace - Powered by CSpace